Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital as of July 31, 2021
August 06 2021 - 12:00PM
Business Wire
In accordance with Articles L.233-8 II of
the French Commercial Code and 223-16 of the General Regulations of
the Autorité des Marchés Financiers (French Financial Markets
Authority)
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris Compartment: B ISIN code: FR0011341205
Website: www.nanobiotix.com
Date
Number of Shares
Outstanding
Total number of voting
rights
Total voting rights, gross
(1)
Total voting rights, net
(2)
July 31, 2021
34 825 872
35 977 825
35 977 825
(1) The total number of gross (or “theoretical”) voting rights
is used as the basis for calculating threshold crossings. In
accordance with Article 223-11 of the AMF General Regulations, this
number is calculated on the basis of all shares to which voting
rights are attached, including those for which voting rights have
been suspended.
(2) The total number of net (or “exercisable at a Shareholders’
Meeting”) voting rights is calculated without taking into account
shares for which voting rights have been suspended. It is released
in order to ensure that the public is properly informed, in
accordance with the AMF recommendation of July 17, 2007.
In addition, an error was made regarding the number of
outstanding shares of the Company as of May 31, 2021 and June 30,
2021, reported in the press releases dated June 8, 2021 and July 8,
2021. The total rights and shares forming the Company’s share
capital as of such dates were identical to that set forth above as
of July 31, 2021.
***
About NANOBIOTIX : http://www.nanobiotix.com Nanobiotix
is a late-stage clinical biotechnology company pioneering
disruptive, physics-based therapeutic approaches to revolutionize
treatment outcomes for millions of patients; supported by people
committed to making a difference for humanity.
The company’s philosophy is rooted in the concept of pushing
past the boundaries of what is known to expand possibilities for
human life. Incorporated in 2003, Nanobiotix is headquartered in
Paris, France. The company also has subsidiaries in Cambridge,
Massachusetts (United States), France, Spain, and Germany.
Nanobiotix has been listed on Euronext: Paris since 2012 and on the
Nasdaq Global Select Market in New York City since December
2020.
Nanobiotix is the owner of more than 30 umbrella patents
associated with three (3) nanotechnology platforms with
applications in 1) oncology; 2) bioavailability and
biodistribution; and 3) disorders of the central nervous
system.
The company's resources are primarily devoted to the development
of its lead product candidate–NBTXR3—which is the product of its
proprietary oncology platform and has already achieved market
authorization in Europe for the treatment of patients with soft
tissue sarcoma under the brand name Hensify®.
For more information about Nanobiotix, visit us at
http://www.nanobiotix.comor follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210806005243/en/
Nanobiotix Nanobiotix Communications Brandon Owens VP,
Communications +1 (617) 852-4835 contact@nanobiotix.com
Nanobiotix Investor Relations Kate McNeil SVP, Investor
Relations +1 (609) 678-7388 investors@nanobiotix.com Media
Relations France – Ulysse Communication Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51 plgermain@ulysse-communication.com US –
Porter Novelli Dan Childs +1 (781) 888-5106
dan.childs@porternovelli.com
Nanobiotix (EU:NANO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Apr 2023 to Apr 2024